Hepion Pharmaceuticals, Inc. (HEPA): רווח נקי למניה ב-12 החודשים האחרונים

סמל ולוגו של המותג Hepion Pharma (HEPA)

Hepion Pharmaceuticals strictly adheres to environmental regulations regarding chemical disposal in its laboratories. Meanwhile, geopolitical instability complicates patent protection and global supplies, as clearly demonstrated by the annual net income per share chart, where the figure stood at -82.03. Business development is based on the strategic outsourcing of clinical trials for liver drugs through external contractors.

HEPA (Hepion Pharmaceuticals) היסטוריית רווח נקי למניה אחת בשנים עשר החודשים האחרונים מ-04.07.2022 עד 14.06.2025

פילוחים אנליטיים של חברת Hepion Pharma (HEPA)

ניתוח בסיסי של החברה:HEPA - Hepion Pharmaceuticals, Inc.
מוצרים מיוצרים של Hepion Pharmaceuticals Inc.

Analyzing the rolling earnings per share trend, we see the current state of the biotech issuer Hepion Pharmaceuticals (HEPA). This indicator reflects the net income remainder distributed across the total volume of issued securities for the year. The metric is sensitive to operating losses and the volume of equity capital. For a company in the liquidation stage following failed clinical trials, this figure captures the cash burn rate. The negative trend confirms a critical crisis in the business model.